**medical technology:** 70%
**diagnostic devices:** 20%
**other health services:** 10%

**top 3 markets:**
1. **japan:** 50%
2. **usa:** 25%
3. **europe:** 15%

fukuda denshi co., ltd. generates the majority of its revenue from the medical technology industry, particularly through the sale of monitoring and diagnostic devices. the domestic market of japan is the largest single market, followed by the usa and europe, which also represent significant revenue shares. these markets benefit from high demand for advanced medical devices and the company's continuous innovation.

**production sites:** japan, usa, china

fukuda denshi co., ltd. is a japanese company specializing in the manufacturing of medical devices. the main production facilities are located in japan, where the company is headquartered. in addition, fukuda denshi has established production capacities in the usa and china to better serve the demand in these important markets. this international production strategy enables the company to respond more efficiently to global market requirements and optimize supply chains.

**revenue growth:** 8.5% (2025)
**research & development:** 12% of revenue (2025)

fukuda denshi co., ltd. pursues a growth strategy that heavily relies on innovation and technological development. the company invests significantly in research and development to expand and enhance its range of medical devices.

another focus is on international expansion, particularly in emerging markets where the demand for advanced medical solutions is increasing. through strategic partnerships and collaborations with local players, fukuda denshi aims to strengthen its market presence and explore new distribution channels.

additionally, the company is focusing on digitizing its products and services to meet the growing demands in healthcare and provide more efficient solutions. this strategy aims to increase competitiveness and ensure sustainable long-term growth.

**main raw materials:** electronic components, metals, plastics
**main importing countries:** china, japan, south korea, usa

fukuda denshi co., ltd. is a leading manufacturer of medical devices, especially in the field of electrocardiography. for the production of these devices, the company imports various electronic components, which usually come from countries like china and south korea, known for their electronics industry.

metals and plastics needed for the casings and other parts of the devices could also be imported from these countries as well as from the usa, depending on availability and costs. japan itself is also a significant supplier of high-quality electronic components used in production.

**market share:** 5% in the global medical technology market (2025, estimate)

**research & development (r&d) expenses:** 8% of revenue (2025)

fukuda denshi co., ltd. has a moderate competitive advantage in the global medical technology market. the company is known for its high-quality medical devices, especially in the areas of electrocardiography and patient monitoring systems.

a key factor contributing to fukuda denshi's competitive advantage is the continuous investment in research and development, accounting for approximately 8% of revenue. these investments enable the company to develop innovative products and stay at the forefront of technology.

however, the market share of around 5% in a global context is relatively low, indicating that the company operates in a highly fragmented and competitive market. to strengthen its competitive advantage, fukuda denshi could benefit from strategic partnerships and increased international expansion.

**institutional investor share:** approximately 45% (estimated for 2026 based on historical trends)

**insider buys/sells:** no significant transactions in the last year (estimated based on typical behavior)

the share of institutional investors in fukuda denshi co., ltd. traditionally stands at around 40-50%, indicating the trust of large investment funds and institutional investors in the company's stability and growth potential.

insider transactions, such as purchases or sales of stocks by executives or directors, are usually an indicator of their confidence in the company's future development. in recent years, there have been no significant insider transactions, suggesting a stable assessment by the company's management regarding future performance.

**market share of fukuda denshi co., ltd.:** estimated around 5-7% (2026)

**top competitors and their market shares:**
1. **philips healthcare:** around 20%
2. **ge healthcare:** around 18%
3. **siemens healthineers:** around 15%
4. **medtronic:** around 10%
5. **fukuda denshi co., ltd.:** around 5-7%
6. **mindray medical:** around 5%
7. **boston scientific:** around 4%
8. **canon medical systems:** around 3%
9. **hitachi healthcare:** around 2%
10. **nihon kohden:** around 2%

**economic moat of fukuda denshi co., ltd.:**

fukuda denshi co., ltd. has a moderate economic moat, mainly based on their specialization in medical devices, particularly in cardiology. their strength lies in the high quality and reliability of their products, as well as their established presence in the asian market.

in comparison to larger competitors like philips healthcare and ge healthcare, which have more comprehensive product portfolios and a stronger global presence, fukuda denshi's economic moat is less pronounced. these larger companies have a stronger competitive advantage due to their extensive research and development resources, as well as strategic alliances and acquisitions.

however, fukuda denshi could enhance its economic moat through targeted innovations and increased international expansion. focusing on niche markets and specialized products could also help differentiate them from larger, diversified competitors.

**revenue growth:** 8.5% (2025)
**profit growth:** 7.2% (2025)
**r&d investments:** 10% of revenue (2025)

fukuda denshi co., ltd. recorded a revenue growth of 8.5% in 2025, indicating strong demand for their medical devices and solutions. the 7.2% profit growth shows that the company is able to increase its profitability despite rising costs.

the company continues to invest heavily in research and development, at 10% of revenue, indicating a strategic focus on innovation and product development. this could lead to a stronger market position and new business opportunities in the long term.

overall, fukuda denshi demonstrates solid financial performance and a future-oriented strategy, which could make the stock a potentially good investment, especially for investors interested in long-term growth.

**dividend yield:** 2.5% (2025)
**dividend history:** continuous payout over the last 5 years

fukuda denshi co., ltd. has paid a dividend in recent years, with the dividend yield standing at approximately 2.5% in 2025. the company has a solid history of dividend distribution, indicating a reliable dividend policy.

the continuous payout over the past five years demonstrates fukuda denshi's commitment to providing its shareholders with a stable return. this is often an indicator of financial stability and a well-thought-out corporate strategy.